Bumped kinase inhibitor 1294 treats established toxoplasma gondii infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3547-3549

  Doggett, J Stone ^a,b   Ojo, Kayode K ^c   Fan, Erkang ^d   Maly, Dustin J ^c   Van Voorhis, Wesley C ^c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUMPED KINASE INHIBITOR 1294; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; CALCIUM-DEPENDENT PROTEIN KINASE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTOZOAL PROTEIN; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; TACHYZOITE; TOXOPLASMOSIS; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; TOXOPLASMA;

ANIMALS; ANTIPROTOZOAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NAPHTHALENES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTOZOAN PROTEINS; PYRAZOLES; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84901277406     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01823-13     Document Type: Article

References (12)

1. Gilbert RE, Freeman K, Lago EG, Bahia-Oliveira LM, Tan HK, Wallon M, Buffolano W, Stanford MR, Petersen E. 2008. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl. Trop. Dis. 2:e277. http://dx.doi.org/10.1371/journal.pntd.0000277.
2. Demar M, Hommel D, Djossou F, Peneau C, Boukhari R, Louvel D, Bourbigot AM, Nasser V, Ajzenberg D, Darde ML, Carme B. 2012. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin. Microbiol. Infect. 18:E221-E231. http://dx.doi.org/10.1111/j.1469- 0691.2011.03648.x.
3. Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley LD. 2010. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature 465:359-362. http://dx.doi.org/10.1038/nature09022.
4. Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, Derocher AE, Inampudi KK, Kim JE, Arakaki TL, Murphy RC, Zhang L, Napuli AJ, Maly DJ, Verlinde CL, Buckner FS, Parsons M, Hol WG, Merritt EA, Van Voorhis WC. 2010. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat. Struct. Mol. Biol. 17:602-607. http://dx.doi.org/10.1038/nsmb.1818.
5. Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CL, White AC, Jr, Merritt EA, Van Voorhis WC, Maly DJ. 2010. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med. Chem. Lett. 1:331-335. http://dx.doi.org/10.1021/ml100096t.
6. Sugi T, Kobayashi K, Takemae H, Gong H, Ishiwa A, Murakoshi F, Recuenco FC, Iwanaga T, Horimoto T, Akashi H, Kato K. 2013. Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1. Int. J. Parasitol. Drugs Drug Resist. 3:93-101. http://dx.doi.org/10.1016/j.ijpddr.2013. 04.001.
7. Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, Parsons M, Van Voorhis WC, Maly DJ. 2012. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J. Med. Chem. 55:2416-2426. http://dx.doi.org/10.1021/ jm201713h.
8. Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AM, Reid MC, Dale EJ, Perera BG, Kim J, Hewitt SN, Hol WG, Verlinde CL, Fan E, Van Voorhis WC, Maly DJ, Merritt EA. 2012. Multiple determinants for selective inhibition of apicomplexan calciumdependent protein kinase CDPK1. J. Med. Chem. 55:2803-2810. http://dx.doi.org/10.1021/jm201725v.
9. Lourido S, Zhang C, Lopez MS, Tang K, Barks J, Wang Q, Wildman SA, Shokat KM, Sibley LD. 2013. Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii. J. Med. Chem. 56:3068-3077. http://dx.doi.org/10.1021/jm4001314.
10. Ojo KK, Eastman RT, Vidadala R, Zhang Z, Rivas KL, Choi R, Lutz JD, Reid MC, Fox AMW, Hulverson MA, Kennedy M, Isoherranen N, Kim LM, Comess KM, Kempf DJ, Verlinde CLMJ, Su X, Kappe S, Maly DJ, Fan E, Van Voorhis WC. 2014. A specific inhibitor of PfCDPK4 blocks malaria transmission: Chemical-genetic validation. J. Infect. Dis. 209: 275-284. http://dx.doi.org/10.1093/infdis/ jit522.
11. Castellanos-Gonzalez A, White AC, Jr, Ojo KK, Vidadala RS, Zhang Z, Reid MC, Fox AM, Keyloun KR, Rivas K, Irani A, Dann SM, Fan E, Dustin J, Van Voorhis WC. 2013. A novel calcium dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J. Infect. Dis. 208:1342-1348. http://dx.doi.org/10.1093/infdis/jit327.
12. Sugi T, Kato K, Kobayashi K, Kurokawa H, Takemae H, Gong H, Recuenco FC, Iwanaga T, Horimoto T, Akashi H. 2011. 1NM-PP1 treatment of mice infected with Toxoplasma gondii. J. Vet. Med. Sci. 73: 1377-1379. http://dx.doi.org/10.1292/ jvms.11-0085.